Inotuzumab Ozogamicin

證據等級: L5

預測適應症: 10 個

Inotuzumab Ozogamicin: From B-cell Precursor Acute Lymphoblastic Leukaemia to Drug-Induced Osteoporosis

One-Sentence Summary

Inotuzumab ozogamicin is a CD22-targeted antibody-drug conjugate (ADC), clinically established for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL). The TxGNN model’s top-ranked prediction for this drug is drug-induced osteoporosis, but this signal is supported by 0 clinical trials and 0 publications, and the evidence pack itself flags it as a likely false-positive artefact rather than a genuine repurposing candidate.

Quick Overview

Item	Content
Original Indication	Not captured in TGA/ARTG data (drug not marketed in Australia). Per supporting evidence text, internationally used for CD22-positive B-cell precursor acute lymphoblastic leukaemia
Predicted New Indication	Drug-induced osteoporosis
TxGNN Prediction Score	98.24%
Evidence Level	L5 (model prediction only, no supporting studies)
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, inotuzumab ozogamicin is an ADC combining a CD22-targeting antibody with the cytotoxic payload calicheamicin, and it is internationally used for CD22-positive B-cell precursor ALL — a mechanism entirely distinct from bone metabolism.

The predicted indication, drug-induced osteoporosis, has no established biological link to the CD22/calicheamicin pathway. There is no known interaction between CD22 signalling and bone remodelling regulators such as RANKL/OPG. The evidence pack’s own rationale assessment concludes this is most likely a byproduct of the drug’s known myelosuppressive toxicity profile being confounded with a treatable indication — a common failure mode for ADC-class drugs in knowledge-graph predictions — rather than a genuine therapeutic mechanism.

In short: this is a high TxGNN score without any corroborating mechanistic, preclinical, trial, or literature support, and the supplied rationale explicitly characterises it as prediction noise rather than a treatment hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

Inotuzumab ozogamicin has no ARTG entries and is not currently marketed in Australia (0 registered products).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (antibody-drug conjugate; calicheamicin cytotoxic payload)
Myelosuppression Risk	High — known to induce thrombocytopenia and neutropenia; also associated with hepatotoxicity/veno-occlusive disease (VOD/SOS)
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Full blood count (FBC) with differential, liver function tests, renal function
Handling Protection	Cytotoxic drug handling precautions required, consistent with ADC/cytotoxic conjugate class

Safety Considerations

Key warnings, contraindications, and drug interaction data are not available in this evidence pack (TGA/PI warning data is flagged as a Blocking-severity data gap). As the drug is not currently marketed in Australia, no TGA-approved Product Information exists — safety assessment should rely on the overseas regulatory label pending Australian registration.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication carries no clinical trial or literature support (Evidence Level L5), and the evidence pack’s own mechanistic assessment identifies it as a likely false-positive signal rather than a plausible biological link. Combined with the drug’s unregistered status in Australia and missing safety/MOA data, there is no basis to advance this candidate.

To proceed, the following is needed:

Confirmed mechanism of action data (DrugBank or primary literature)
TGA/PI-equivalent safety and warning data (currently a blocking gap)
Independent biological plausibility review of any bone-metabolism pathway link before further evidence collection is warranted
If pursued, preclinical or mechanistic studies to establish a genuine rationale, since none currently exists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.